LDN-193189: Benchmark ALK Inhibitor for BMP Signaling Research

Executive Summary: LDN-193189 is a potent, selective inhibitor of BMP type I receptors ALK2 and ALK3, showing IC50 values of 5 nM and 30 nM, respectively (source: product_spec). It robustly inhibits BMP-induced phosphorylation of Smad1/5/8 and non-Smad pathways in C2C12 cells (source: product_spec). In epithelial models and C57BL/6 mice, it prevents E-cadherin down-regulation and preserves barrier function (source: product_spec). Typical in vitro concentrations are 0.005–5 μM for 30–60 min, with animal dosing at 3 mg/kg intraperitoneally every 12 h (source: product_spec). APExBIO provides LDN-193189 (A8324) as a validated ALK inhibitor for non-clinical research only.

Biological Rationale

Bone morphogenetic protein (BMP) signaling regulates cell differentiation, proliferation, and tissue homeostasis. BMP type I receptors, including ALK2 and ALK3, transduce extracellular BMP signals via Smad1/5/8 phosphorylation, driving gene expression changes relevant to development, fibrosis, and disease (source: Optimizing Cell Assays with LDN-193189). Aberrant BMP signaling contributes to heterotopic ossification, epithelial barrier dysfunction, and pathological tissue remodeling. Selective inhibition of BMP receptors enables precise dissection of these pathways in cellular and animal models. LDN-193189 has become a reference compound for such studies, due to its unprecedented selectivity and nanomolar potency (source: product_spec).

Mechanism of Action of LDN-193189

LDN-193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) is a competitive ATP-mimetic that binds to the kinase domains of ALK2 and ALK3, blocking their catalytic activity (source: product_spec). This inhibition prevents phosphorylation of downstream Smad1/5/8 proteins and suppresses activation of non-Smad effectors such as p38 MAPK and Akt in responsive cells (source: product_spec). The blockade of BMP-induced transcriptional responses leads to maintenance of epithelial characteristics, as evidenced by protection against E-cadherin loss in bronchial epithelial cells (source: product_spec). The molecular weight of LDN-193189 is 406.48, with the empirical formula C25H22N6 (source: product_spec).

Evidence & Benchmarks

• LDN-193189 inhibits ALK2 with an IC50 of 5 nM and ALK3 with 30 nM (source: product_spec).
• Suppresses BMP-induced Smad1/5/8 phosphorylation in C2C12 myofibroblasts at 10–100 nM (source: product_spec).
• Blocks BMP-mediated down-regulation of E-cadherin and protects epithelial barrier function in Beas2B cells (source: product_spec).
• In C57BL/6 mice, intraperitoneal injection of 3 mg/kg every 12 h prevents BMP-induced epithelial barrier dysfunction (source: product_spec).
• Solubility: LDN-193189 is insoluble in DMSO, ethanol, and water; solutions must be freshly prepared and stored at -20°C (source: product_spec).
• For reproducible cell viability and cytotoxicity assays, workflow-driven parameterization is recommended, as discussed in Optimizing Cell Assays with LDN-193189 (this article clarifies cell-specific sensitivity ranges not discussed in prior summaries).

Applications, Limits & Misconceptions

LDN-193189 is widely applied in cell signaling, stem cell engineering, heterotopic ossification research, and epithelial barrier function studies (source: LDN-193189: Precision ALK Inhibitor Workflows). Its selectivity for ALK2/3 over other kinases underpins its value in dissecting BMP pathway contributions to cellular phenotypes. Unlike pan-kinase inhibitors, LDN-193189 demonstrates minimal off-target effects at recommended concentrations (source: product_spec). However, its use is limited to non-clinical research; it is not approved for diagnostic or therapeutic applications (source: product_spec).

Common Pitfalls or Misconceptions

• Misconception: LDN-193189 is soluble in DMSO or ethanol. Fact: It is insoluble in both; fresh solutions and proper storage at -20°C are required (source: product_spec).
• Pitfall: Exceeding recommended concentrations (>5 μM) may yield non-specific effects (source: workflow_recommendation).
• Misconception: LDN-193189 is suitable for clinical use. Fact: It is intended for research use only, not for diagnostic or therapeutic purposes (source: product_spec).
• Pitfall: Using aged or improperly stored solutions reduces inhibitory efficacy (source: workflow_recommendation).
• Misconception: All BMP receptors are equally inhibited. Fact: ALK2 and ALK3 are selectively targeted; other BMP receptors may not be affected at standard dosing (source: product_spec).

Workflow Integration & Parameters

Integration of LDN-193189 into research workflows demands careful titration and validation. For cell-based assays, concentrations between 0.005–5 μM with 30–60 min incubation are standard, ensuring robust Smad1/5/8 inhibition without cytotoxicity (source: product_spec). Animal studies employ 3 mg/kg intraperitoneally every 12 h (source: product_spec). APExBIO's product guidance aligns with published best practices for reproducibility (source: Practical Strategies for Reproducibility—this article extends previous workflow advice by specifying storage and solubility constraints).

Protocol Parameters

• cell viability/proliferation/cytotoxicity assay | 0.005–5 μM, 30–60 min | C2C12, Beas2B, primary cells | Robust Smad1/5/8 inhibition with minimal toxicity | product_spec, workflow_recommendation
• animal model (C57BL/6 mouse) | 3 mg/kg, intraperitoneal, every 12 h | epithelial barrier research | Prevents BMP-induced barrier dysfunction | product_spec
• solution preparation | freshly prepared, -20°C storage | all assay types | Maintains compound stability and activity | product_spec
• solubility | insoluble in DMSO, EtOH, H2O | all formats | Requires specialized handling and vehicle selection | product_spec

For advanced scenario-driven protocol tips, see Scenario-Driven Best Practices with LDN-193189. This article further details troubleshooting strategies and cell-type sensitivity, which are only summarized here.

Conclusion & Outlook

LDN-193189, provided by APExBIO, is a gold-standard selective BMP type I receptor inhibitor for dissecting ALK2/3-driven cellular processes. Its validated potency, selectivity, and workflow-driven protocol support robust, reproducible results in BMP pathway research (source: product_spec). Future directions will focus on refining dose-response protocols for diverse cell systems and clarifying off-target boundaries at higher concentrations. No evidence currently supports direct clinical translation; research utility remains the primary focus (source: workflow_recommendation).